Format

Send to

Choose Destination
Target Oncol. 2016 Jun;11(3):345-51. doi: 10.1007/s11523-015-0396-3.

Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.

Author information

1
Medical Oncology, University and Hospital Trust, Verona, Italy.
2
Department of Pathology and Diagnostics, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
3
Urologic Clinic, University and Hospital Trust, Verona, Italy.
4
Internal Medicine, University and Hospital Trust, Verona, Italy.
5
ARC-NET Applied Research Centre, University of Verona, Verona, Italy.
6
Medical Oncology, IRCCS Foundation, University and Hospital Trust, Pavia, Italy.
7
Department of Pathology and Diagnostics, Immunology, University and Hospital Trust, Verona, Italy.
8
Anatomic Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.
9
Deparment of Pathology, University of Queensland, Brisbane, Australia.
10
Department of Pathology and Diagnostics, Anatomic Pathology, University and Hospital Trust, Verona, Italy. matteo.brunelli@univr.it.
11
Department of Pathology and Diagnostics, University of Verona, FISH Lab; P.le. L.A. Scuro n. 10, 37134, Verona, Italy. matteo.brunelli@univr.it.

Abstract

BACKGROUND AND AIM:

Recent therapeutic strategies for castration-resistant prostate cancer have focused on immunomodulation, especially the PD-1/PD-L1 pathway related to tumor-infiltrating lymphocytes. Few cases of castration-resistant prostate adenocarcinoma have been tested simultaneously for PD-1, PD-L1 and T lymphocytes in cancerous tissue. We quantified the PD-1/PD-L1 immune pathway and T lymphocyte infiltrates in a series of patients with castrate-resistant prostate adenocarcinoma.

PATIENTS AND METHODS:

Expression of PD-1, PD-L1, CD3 and FOXP3 was identified in tissue microarrays, with five tissue spots per patient from 16 patients over at least 5 years of follow-up. Two scores were defined. The first described the percentage of PD-1-positive T lymphocytes (CD3+): negative (0), <5 %; low (1+), 5-30 %; high (2+), >30 %. The second described PD-L1 staining intensity: 0 (no signal), 1+ (light signal), 2+ (high signal) in >50 % of neoplastic cells.

RESULTS:

Tumor-infiltrating T lymphocytes (CD3+) were seen in 11/16 cases (69 %). Nine of 16 cases expressed PD-1 (56 %), among which 19 % were scored 2+. Eight of 16 cases expressed PD-L1 (50 %), with 19 % scored as strong 2+. The subgroup with high PD1/PD-L1 also exhibited FOXP3 expression.

CONCLUSIONS:

Approximately 19 % of patients in our series showed simultaneous high PD-1/PD-L1 immunoscores, and were the best candidates for receiving targeted anti-PD-1/PD-L1 immunotherapy, as determined using a tissue based rationale.

PMID:
26566945
DOI:
10.1007/s11523-015-0396-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center